Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase I, Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0575 Administered Alone and in Combination With Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma

NCT01564251 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT01564251
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01564251 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase I, Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0575 Administered Alone and in Combination With Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma
Lead sponsor
Genentech, Inc.
Phase
Phase 1
Overall status
Completed
Start date
March 23, 2012
Completion date
January 11, 2018
Enrollment
104 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, solid tumor